Show simple item record

dc.contributor.authorLedermann, JA
dc.contributor.authorOza, AM
dc.contributor.authorLorusso, D
dc.contributor.authorAghajanian, C
dc.contributor.authorOaknin, A
dc.contributor.authorDean, A
dc.contributor.authorColombo, N
dc.contributor.authorWeberpals, JI
dc.contributor.authorClamp, Andrew R
dc.contributor.authorScambia, G
dc.contributor.authorLeary, A
dc.contributor.authorHolloway, RW
dc.contributor.authorGancedo, MA
dc.contributor.authorFong, PC
dc.contributor.authorGoh, JC
dc.contributor.authorO'Malley, DM
dc.contributor.authorArmstrong, DK
dc.contributor.authorBanerjee, S
dc.contributor.authorGarcia-Donas, J
dc.contributor.authorSwisher, EM
dc.contributor.authorCameron, T
dc.contributor.authorMaloney, L
dc.contributor.authorGoble, S
dc.contributor.authorColeman, RL
dc.date.accessioned2020-06-15T12:57:41Z
dc.date.available2020-06-15T12:57:41Z
dc.date.issued2020en
dc.identifier.citationLedermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(5):710-22.en
dc.identifier.pmid32359490en
dc.identifier.doi10.1016/s1470-2045(20)30061-9en
dc.identifier.urihttp://hdl.handle.net/10541/622981
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/ 10.1016/s1470-2045(20)30061-9en
dc.titleRucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trialen
dc.typeArticleen
dc.contributor.departmentDepartment of Oncology, UCL Cancer Institute, University College London and UCL Hospitals, London, UK.en
dc.identifier.journalLancet Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record